Kuo, Yu-Cheng <br/><br/>
Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.  [electronic resource] 

 -  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie  Feb 2012 
 - 12-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1950-6007 
<br/><br/><label>Standard No.: </label>10.1016/j.biopha.2011.09.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Benzenesulfonates--pharmacology<br/>Blotting, Western<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Colorectal Neoplasms--drug therapy<br/>Combined Modality Therapy<br/>Electrophoretic Mobility Shift Assay<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Male<br/>Mice<br/>Mice, SCID<br/>NF-kappa B--drug effects<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Pyridines--pharmacology<br/>Radiation-Sensitizing Agents--pharmacology<br/>Sorafenib<br/>Xenograft Model Antitumor Assays